Clinical Trial Update: A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating Foretinib in non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Foretinib (foretinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 2 | Status: WITHDRAWN